|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HCFC2 |
Gene summary for HCFC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HCFC2 | Gene ID | 29915 |
| Gene name | host cell factor C2 | |
| Gene Alias | HCF-2 | |
| Cytomap | 12q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9Y5Z7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29915 | HCFC2 | male-WTA | Human | Thyroid | PTC | 5.53e-08 | 3.96e-02 | 0.1037 |
| 29915 | HCFC2 | PTC01 | Human | Thyroid | PTC | 3.51e-05 | 4.57e-02 | 0.1899 |
| 29915 | HCFC2 | PTC04 | Human | Thyroid | PTC | 2.02e-12 | 1.41e-01 | 0.1927 |
| 29915 | HCFC2 | PTC05 | Human | Thyroid | PTC | 5.84e-04 | 1.34e-01 | 0.2065 |
| 29915 | HCFC2 | PTC06 | Human | Thyroid | PTC | 1.62e-12 | 2.31e-01 | 0.2057 |
| 29915 | HCFC2 | PTC07 | Human | Thyroid | PTC | 2.18e-09 | 1.77e-01 | 0.2044 |
| 29915 | HCFC2 | ATC12 | Human | Thyroid | ATC | 2.03e-11 | 2.50e-01 | 0.34 |
| 29915 | HCFC2 | ATC13 | Human | Thyroid | ATC | 3.49e-18 | 2.79e-01 | 0.34 |
| 29915 | HCFC2 | ATC2 | Human | Thyroid | ATC | 3.93e-09 | 5.84e-01 | 0.34 |
| 29915 | HCFC2 | ATC4 | Human | Thyroid | ATC | 2.57e-13 | 3.42e-01 | 0.34 |
| 29915 | HCFC2 | ATC5 | Human | Thyroid | ATC | 3.00e-22 | 3.11e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032113 | Thyroid | PTC | viral process | 236/5968 | 415/18723 | 2.48e-26 | 8.24e-24 | 236 |
| GO:000632520 | Thyroid | PTC | chromatin organization | 183/5968 | 409/18723 | 2.55e-08 | 5.70e-07 | 183 |
| GO:00063385 | Thyroid | PTC | chromatin remodeling | 106/5968 | 255/18723 | 6.56e-04 | 4.13e-03 | 106 |
| GO:001603234 | Thyroid | ATC | viral process | 241/6293 | 415/18723 | 5.50e-25 | 2.04e-22 | 241 |
| GO:0006325110 | Thyroid | ATC | chromatin organization | 189/6293 | 409/18723 | 6.40e-08 | 1.13e-06 | 189 |
| GO:000633813 | Thyroid | ATC | chromatin remodeling | 109/6293 | 255/18723 | 1.38e-03 | 7.15e-03 | 109 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| HCFC2 | cDC | Lung | Healthy | ESD,ERAP2,EPSTI1, etc. | 4.03e-03 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HCFC2 | SNV | Missense_Mutation | c.266N>A | p.Gly89Glu | p.G89E | Q9Y5Z7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |
| HCFC2 | SNV | Missense_Mutation | rs774250277 | c.320N>A | p.Arg107His | p.R107H | Q9Y5Z7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0BO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HCFC2 | SNV | Missense_Mutation | c.451N>C | p.Asp151His | p.D151H | Q9Y5Z7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| HCFC2 | SNV | Missense_Mutation | c.1399T>A | p.Ser467Thr | p.S467T | Q9Y5Z7 | protein_coding | tolerated(0.13) | benign(0.014) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HCFC2 | SNV | Missense_Mutation | c.127N>C | p.Glu43Gln | p.E43Q | Q9Y5Z7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| HCFC2 | SNV | Missense_Mutation | c.1984N>C | p.Gly662Arg | p.G662R | Q9Y5Z7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| HCFC2 | SNV | Missense_Mutation | c.190N>C | p.Val64Leu | p.V64L | Q9Y5Z7 | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| HCFC2 | deletion | Frame_Shift_Del | novel | c.1530_1540delNNNNNNNNNNN | p.Glu510AspfsTer17 | p.E510Dfs*17 | Q9Y5Z7 | protein_coding | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |||
| HCFC2 | SNV | Missense_Mutation | c.826N>A | p.His276Asn | p.H276N | Q9Y5Z7 | protein_coding | tolerated(0.13) | benign(0.171) | TCGA-C5-A7UI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HCFC2 | SNV | Missense_Mutation | novel | c.710N>A | p.Thr237Asn | p.T237N | Q9Y5Z7 | protein_coding | deleterious(0.02) | benign(0.417) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |